Results of a recent TB clinical study suggests a faster, more effective drug treatment for tuberculosis is very close to realization.
A Phase II clinical trial study, published in the UK journal The Lancet, and conducted in South Africa, demonstrated an effective new combination of drugs that killed more than 99 percent of the patient’s tuberculosis bacteria within two weeks. The speed and effectiveness suggest the new regimen could improve upon existing TB treatments for not only general TB, but also drug resistant and TB/HIV co-infected patients.
Historically tuberculosis (often shortened to TB for tubercle bacillus) was a major killer that, while never eradicated, by the 1950’s seemed to be less of a health threat. Modern antibiotic TB treatments and health practices generally reduced the incidence of tuberculosis to the status of a minor disease.
That changed during the 1980s, as strains of TB appeared that were resistant to traditional antibiotics. By the 1990s, the World Health Organization again labeled TB a global health emergency. Continue Reading